CC
C4 Therapeutics, Inc.
CCCC · NASDAQ
$3.76 +1.08% (+$0.04)
1M +3.30%
Market Cap $413.5M
P/E Ratio -
Div. Yield -
ROE 45.45%
Piotroski F-Score Weak
3/9Valuation
48 /100
Fair P/B 1.67x
P/S 11.80x
EV/EBITDA N/A
Growth
36 /100
Stable Book val. growth 3.91%
Rev. growth 4.95%
FCF growth N/A
Profitability
20 /100
Weak Net margin 289.44%
Op. margin 318.97%
FCF margin 243.71%
Quality
1 /100
Poor ROE 45.45%
ROA 28.22%
Asset turnover 0.10x
Debt
100 /100
Low Current ratio 5.45x
Debt/Equity 0.23x
Net debt/EBITDA N/A
Stability
25 /100
Unstable Rev. volatility 53.38%
EPS volatility 22.62%
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre CCCC
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Andrew J. Hirsch
Employees
104
Headquarters
Watertown
Evenimente viitoare
05 NOV.
Earnings
Upcoming earnings report